Introduction
Nasopharyngeal carcinoma (NPC) is a very rare malignancy in children and adolescents. The incidence of NPC of the age range 1-19 years in Korea was as follows: the total number of cases was 58, and age standardized rate was 0.4 per million between 1999 and 2007 [1] . The World Health Organization (WHO) classification categorizes NPC into the following groups: keratinizing squamous cell carcinoma (type I), non-keratinizing squamous carcinoma (type II), and undifferentiated carcinoma (type III). Type II and III are well known to be related to latent Epstein-Barr virus (EBV) infection [2, 3] . Undifferentiated carcinoma, which is associated with advanced locoregional disease and high incidence of distant metastasis, is the most common type of NPC in pediatric patients [4] .
Treatment of adult NPC has evolved over the past two decades. Radiotherapy (RT) is usually successful in controlling early stage NPC, but survival rates decrease in patients with advanced locoregional disease. Recently, various combinations of concurrent, neo-adjuvant, and adjuvant chemotherapy were evaluated [5] . However, there are no definite optimal treatment strategies for pediatric patients with NPC owing to the rarity of this cancer.
Single institution data of pediatric patients with advanced stage NPC treated with RT and chemotherapy are presented.
The results expand our understanding of the clinical characteristics, treatment outcomes, and toxicities in pediatric NPC.
Materials and Methods

1) Patients and study design
The medical records of newly diagnosed NPC patients treated at the Seoul National University Children's Hospital between 1988 and 2012 were reviewed. The study included 9 patients (6 boys and 3 girls), with a median age of 11 years at diagnosis (range, 9-13 years). 
4) Response and toxicity evaluation
Response was evaluated at the following time points in the treatment protocol: after the third cycle of chemotherapy (neoadjuvant chemotherapy), after concurrent chemoradiotherapy (CCRT), and after completion of treatment.
Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events v4.0.
5) Statistical analysis
The overall survival (OS) was calculated from the date of diagnosis to death or the date of last follow-up. The event-free survival (EFS) was calculated from the date of diagnosis to the date of the event or the date of last follow-up if the patient did not have events. Events were defined as death owing to disease progression, relapse, secondary malignancy, or treatment-related mortality (TRM).
Kaplan-Meier analysis was used to estimate the OS and EFS.
6) Ethics statement
This study was approved by the institutional review boards of the Seoul National University Hospital, Seoul, Korea (IRB number: 1407-008-591). Informed consent was waived by the board. Causes of death were disease progression in 1 patient and sepsis in 1 patient ( Table 1 ). The OS was 77.8%, and the EFS was 38.9% (Fig. 2) .
Results
1) Baseline characteristics
3) Toxicity and treatment-related mortalities
The most common acute toxicities were oropharyngeal mucositis and febrile neutropenia for all patients. Treatment-related mortality was one. He died of sepsis due to Klebsiella pneumoniae. 5-FU-induced neurotoxicity was suspected in 6 patients. The symptoms were dysarthria, 
Discussion
In accordance with previous reports, undifferentiated carcinoma comprising 77.8% of the cases was the most frequent histologic type of NPC observed in our study [6, 7] .
Downing et al. reported that more advanced diseases are more frequently seen in young patients (under 25 years) than in adults [8] . In our study, most patients (88.9%) had advanced stage disease (stage III or IV). EBER ISH was positive in all patients evaluated, all of whom had type III histology. On the basis of the positivity of EBER ISH, it is likely that type III NPC is associated with EBV infection.
Although the high incidence of advanced stage NPC in pediatric patients could be explained by the high prevalence of type III histology, other factors may also contribute to this. The initial symptoms of NPC such as otalgia, cervical lymph node enlargement, and epistaxis may also be present in healthy children. Because the incidence of NPC is low, these initial symptoms may often be ignored.
It is well known that NPC is a radiosensitive cancer, but RT alone resulted in poor overall survival in pediatric patients with advanced NPC [9, 10] . In recent years, chemoradiotherapy demonstrated a survival benefit compared with RT alone in several adult studies [11] [12] [13] [14] . Bachouchi et al. reported therapeutic effects of three drug regimen consisting of cisplatin, bleomycin, and 5-FU with RT for metastatic and locoregional NPC [15] . Subsequently, they modified their combination, substituting epirubicin for 5-FU, and treatment results showed high complete response [16] . We applied these regimens with modifying the dose and duration of treatment. Compared with the GPOH-NPC-91 study, our regimen comprised much more cycles of chemotherapy, even though there was no significant difference of total treatment duration [17] . There were several trials with various combinations of chemotherapy and RT, but only our study used all 3 combinations of CCRT, neoadjuvant and adjuvant chemotherapy. Furthermore, researchers have not shown better outcomes by adding neoadjuvant or adjuvant chemotherapy than CCRT alone until now [18, 19] . In our study, the overall response rates after neoadjuvant chemotherapy and after CCRT were 55.6% and Several studies have reported the association of RT dose and local tumor control [4, 20] . However, patients who received high dose RT experienced significant morbidity. Hu et al. reported that RT doses ＞70 Gy may increase sensorineural hearing loss and growth hormone deficiency [6] .
Lower radiation doses with chemotherapy were applied to pediatric patients owing to the late effects of RT. In a prospective study, Mertens et al. [17] demonstrated that combined chemotherapy allows the RT dose to be reduced to ＜60 Gy. We reduced the total RT dose to ＜60 Gy in all patients. Our data suggest that the combination of RT and chemotherapy could be effective to control advanced NPC and reduce RT-related late toxicities in pediatric patients.
Unfortunately, severe toxicities associated with chemotherapeutic agents occurred in 2 patients. In this study, toxicities were the main cause of treatment failure and death.
However, most treatment complications were temporary and reversible. Cerebellar dysfunction and encephalopathy have been relatively well known as neurotoxicity of 5-FU, but peripheral neuropathy could be also associated with 5-FU therapy [21] . Whereas the most common neurotoxicity of cisplatin is peripheral neurotoxicity, and the onset of toxicity is delayed until a cumulative dose higher than 300 mg/m 2 [22] . Cerebellar dysfunction, encephalopathy or peripheral neuropathy was presented in 6 of the 9 patients.
In this regard neurologic side effects of the patients may be induced by 5-FU rather than cisplatin, and we decided to discontinue or reduce 5-FU. Our data demonstrated good survival rates in pediatric NPC patients after treatment with a combination of systemic chemotherapy and RT. We expect that reduction of the RT dose combined with the addition of neoadjuvant and concomitant chemotherapy will aid long-term survival. To improve outcomes, new strategies to decrease toxicities are needed. Prospective randomized studies in pediatric groups will lead to treatments that are more effective.
